875479-34-8

Basic information

• Product Name: Cyclopropanecarboxylic acid, 2-(4-bromophenyl)-, ethyl ester, (1S,2S)-
• CAS NO: 875479-34-8
• Molecular Formula: C12H13BrO2
• Molecular Weight: 269.138
• Mol File: 875479-34-8.mol
• Article Data: 13

Chemical Properties

• CAS DataBase Reference: Cyclopropanecarboxylic acid, 2-(4-bromophenyl)-, ethyl ester, (1S,2S)-(CAS DataBase Reference)
• NIST Chemistry Reference: Cyclopropanecarboxylic acid, 2-(4-bromophenyl)-, ethyl ester, (1S,2S)-(875479-34-8)
• EPA Substance Registry System: Cyclopropanecarboxylic acid, 2-(4-bromophenyl)-, ethyl ester, (1S,2S)-(875479-34-8)

Safety Data

• Hazardous Substances Data: 875479-34-8(Hazardous Substances Data)

Upstream product

• 623-73-4 diazoacetic acid ethyl ester 
• 2039-82-9 1-bromo-4-ethenyl-benzene 
• 1029431-48-8 (R)-1-(4-bromophenyl)-2-chloroethanol 
• 4209-02-3 1-(4-bromophenyl)-2-chloroethan-1-one 
• 867-13-0 diethoxyphosphoryl-acetic acid ethyl ester 
• 62566-68-1 (R)-2-(4-bromophenyl)oxirane 

Downstream Products

• 1207748-06-8 ethyl (1S,2S)-2-[4-(2-cyclopropyl-1,3-oxazol-4-yl)phenyl]cyclopropanecarboxylate 
• 1123620-89-2 (1S,2S)-2-(4-bromophenyl)cyclopropanecarboxylic acid 
• 1119807-02-1 AZD₅₂₁₃ 
• 1241093-84-4 (1S, 2S)-2-(4-Carbamoyl-phenyl)-cyclopropanecarboxylic acid 
• 1240914-90-2 (1S,2S)-2-(4-cyano-phenyl)-cyclopropanecarboxylic acid 
• 1242441-31-1 (1S,2S)-2-(4-{5-[(5-chloropyridin-2-yl)thio]-1-methyl-1H-imidazol-4-yl}phenyl)-N-(2-fluoroethyl)cyclopropanecarboxamide 
• 1242441-32-2 (1S,2S)-2-(4-{5-[(5-chloropyridin-2-yl)thio]-1-methyl-1H-imidazol-4-yl}phenyl)-N-(2-fluoroethyl)-N-methylcyclopropanecarboxamide 
• 1242441-05-9 ethyl (1S,2S)-2-[4-(5-iodo-1-methyl-1H-imidazol-4-yl)phenyl]cyclopropanecarboxylate 
• 1242441-17-3 (1S,2S)-ethyl 2-(4-(5-((5-chloropyridin-2-yl)thio)-1-methyl-1H-imidazol-4-yl)phenyl)cyclopropanecarboxylate 
• 1242441-07-1 (1S,2S)-2-(4-{5-[(5-chloropyridin-2-yl)thio]-1-methyl-1H-imidazol-4-yl}phenyl)cyclopropanecarboxylic acid 
• 1242440-98-7 (1S,2S)-ethyl 2-(4-(1H-imidazol-4-yl)phenyl)cyclopropanecarboxylate 
• 1319211-95-4 (1S,2S)-ethyl 2-(4-(5-iodo-1H-imidazol-4-yl)phenyl)cyclopropanecarboxylate 
• 1242441-48-0 (1S,2S)-ethyl 2-(4-(5-((5-chloropyridin-2-yl)thio)-1H-imidazol-4-yl)phenyl)cyclopropanecarboxylate 
• 1242441-49-1 (1S,2S)-2-(4-(5-((5-chloropyridin-2-yl)thio)-1H-imidazol-4-yl)phenyl)cyclopropanecarboxylic acid 

Relevant articles and documents

Stereoselective Cyclopropanation of Electron-Deficient Olefins with a Cofactor Redesigned Carbene Transferase Featuring Radical Reactivity

Engineered myoglobins and other hemoproteins have recently emerged as promising catalysts for asymmetric olefin cyclopropanation reactions via carbene-transfer chemistry. Despite this progress, the transformation of electron-poor alkenes has proven to be very challenging using these systems. Here, we describe the design of a myoglobin-based carbene transferase incorporating a non-native iron-porphyrin cofactor and axial ligand, as an efficient catalyst for the asymmetric cyclopropanation of electron-deficient alkenes. Using this metalloenzyme, a broad range of both electron-rich and electron-deficient alkenes are cyclopropanated with high efficiency and high diastereo- A nd enantioselectivity (up to >99% de and ee). Mechanistic studies revealed that the expanded reaction scope of this carbene transferase is dependent upon the acquisition of metallocarbene radical reactivity as a result of the reconfigured coordination environment around the metal center. The radical-based reactivity of this system diverges from the electrophilic reactivity of myoglobin and most of the known organometallic carbene-transfer catalysts. This work showcases the value of cofactor redesign toward tuning and expanding the reactivity of metalloproteins in abiological reactions, and it provides a biocatalytic solution to the asymmetric cyclopropanation of electron-deficient alkenes. The metallocarbene radical reactivity exhibited by this biocatalyst is anticipated to prove useful in the context of a variety of other synthetic transformations.

Crystalline Form Of A Cyclopropyl Benzamide Derivative

The present invention relates to a crystalline form of compound (I), 4-{(1S,2S)-2-[(4-cyclobutylpiperazin-1-yl)carbonyl]-cyclopropyl}-benzamide, pharmaceutical formulations containing said compound and to the use of said active compound in therapy.

OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH

The present invention is directed to certain oxazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzheimer Disease, and Parkinson's Disease.